A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications.
Jacob SchönGüliz Tuba BarutBettina Salome TrueebNico Joël HalweInês Berenguer VeigaAnnika KratzelLorenz UlrichJenna N KellyMelanie BrüggerChristoph LangnerAdriano TaddeoEtori Aguiar MoreiraDemeter TúrósLlorenç Grau-RomaAnn Kathrin AhrensKore SchlottauTobias BritzkeAngele BreithauptBjörn CorleisJana KochmannBlandina I Oliveira EstevesLea AlmeidaLisa ThomannChristelle DevismeHanspeter StalderSilvio SteinerSarah OchsenbeinKimberly SchmiedFabien LabroussaaJoerg JoresPhilip V'kovskiVladimir CmiljanovicMarco P AlvesCharaf BenarafaNadine EbertDonata HoffmannMartin BeerVolker ThielPublished in: Nature microbiology (2024)
Approved vaccines are effective against severe COVID-19, but broader immunity is needed against new variants and transmission. Therefore, we developed genome-modified live-attenuated vaccines (LAV) by recoding the SARS-CoV-2 genome, including 'one-to-stop' (OTS) codons, disabling Nsp1 translational repression and removing ORF6, 7ab and 8 to boost host immune responses, as well as the spike polybasic cleavage site to optimize the safety profile. The resulting OTS-modified SARS-CoV-2 LAVs, designated as OTS-206 and OTS-228, are genetically stable and can be intranasally administered, while being adjustable and sustainable regarding the level of attenuation. OTS-228 exhibits an optimal safety profile in preclinical animal models, with no side effects or detectable transmission. A single-dose vaccination induces a sterilizing immunity in vivo against homologous WT SARS-CoV-2 challenge infection and a broad protection against Omicron BA.2, BA.5 and XBB.1.5, with reduced transmission. Finally, this promising LAV approach could be applicable to other emerging viruses.